This company listing is no longer active
CMOTEC BTA B Stock Overview
Offers cancer care and pain management solutions in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Scandinavian ChemoTech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.65 |
| 52 Week High | SEK 2.69 |
| 52 Week Low | SEK 1.25 |
| Beta | 1.34 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 89.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMOTEC BTA B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 2.3% | -0.1% | 1.6% |
| 1Y | n/a | 3.8% | 21.2% |
Return vs Industry: Insufficient data to determine how CMOTEC BTA B performed against the Swedish Medical Equipment industry.
Return vs Market: Insufficient data to determine how CMOTEC BTA B performed against the Swedish Market.
Price Volatility
| CMOTEC BTA B volatility | |
|---|---|
| CMOTEC BTA B Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in SE Market | 11.0% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: CMOTEC BTA B's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CMOTEC BTA B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 6 | Stefan Frick | chemotech.se |
Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses.
Scandinavian ChemoTech AB (publ) Fundamentals Summary
| CMOTEC BTA B fundamental statistics | |
|---|---|
| Market cap | SEK 40.18m |
| Earnings (TTM) | -SEK 19.26m |
| Revenue (TTM) | SEK 4.11m |
9.8x
P/S Ratio-2.1x
P/E RatioIs CMOTEC BTA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMOTEC BTA B income statement (TTM) | |
|---|---|
| Revenue | SEK 4.11m |
| Cost of Revenue | SEK 442.00k |
| Gross Profit | SEK 3.67m |
| Other Expenses | SEK 22.93m |
| Earnings | -SEK 19.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 89.25% |
| Net Profit Margin | -468.27% |
| Debt/Equity Ratio | 0% |
How did CMOTEC BTA B perform over the long term?
See historical performance and comparison